Insider · CIK 0001764435
LAV Biosciences Fund V, L.P.
owner
Files at ADRX (ADARx Pharmaceuticals, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stock | +8,908,775 | - | - | 8,908,775 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stock | +1,667,469 | - | - | 10,576,244 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stock | +513,067 | - | - | 11,089,311 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stock | +153,868 | - | - | 11,243,179 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: By LAV Fund VI, L.P. | +307,738 | - | - | 307,738 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: By LAV Fund VI Opportunities, L.P. | +307,738 | - | - | 307,738 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series A Preferred Stockderivative | -10,438,412 | $0.00 | $0 | 0 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B Preferred Stockderivative | -1,953,774 | $0.00 | $0 | 0 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B-1 Preferred Stockderivative | -601,161 | $0.00 | $0 | 0 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series C Preferred Stockderivative | -180,288 | $0.00 | $0 | 0 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series C Preferred Stockderivativeindirect: By LAV Fund VI, L.P. | -360,577 | $0.00 | $0 | 0 | 13 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series C Preferred Stockderivativeindirect: By LAV Fund VI Opportunities, L.P. | -360,577 | $0.00 | $0 | 0 | 13 d ago |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.